GDM. endocrine, nutritional and metabolic diseases
Conditions
Interventions
Intervention 1: Intervention group: Ginger capsule, 500 mg, orally, daily (one capsule every 12 hours) for 8 weeks. Intervention 2: Control group: placebo, orally, quite similar to ginger capsule, dai
Treatment - Drugs
Intervention group: Ginger capsule, 500 mg, orally, daily (one capsule every 12 hours) for 8 weeks
Control group: placebo, orally, quite similar to ginger capsule, daily (one capsule every 12 hours) for 8 weeks
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Having an ultrasound based on singleton pregnancy; Gestational age between 24-28 weeks; Pregnant women aged 18-35 years; Pregnant woman with gestational diabetes who inject insulin and respond to insulin treatment; Normal blood pressure (less than 140/90 mmHg) in the current pregnancy and the absence of proteinuria in pregnancy tests; have at least read and write literacy; Willingness to participate in the study; Having telephone number and address for follow up; Having health records in Taleghani and ALzahra hospitals in Tabriz. Exclusion criteria: Alcohol or tobacco consumption; The use of traditional medicines, especially cinnamon; Mothers with a history of chronic hypertension; Blood glucose less than 70 mg/dl
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood sugar before and after of intervention in groups of study. Timepoint: Before intervention 2, 4, 6 and 8 weeks after intervention. Method of measurement: Laboratory and check list.;Average blood sugar 2 hours after meals before and after intervention in groups of study. Timepoint: Before intervention2,4, 6 and 8 weeks after intervention. Method of measurement: Laboratory and check lists.;Insulin dose in the study groups. Timepoint: 8 weeks after intervention. Method of measurement: check lists. | — |
Secondary
| Measure | Time frame |
|---|---|
| Frequency of side events in the study groups. Timepoint: 8 weeks after intervention. Method of measurement: The side events check list.;Number of specialist physician visits to control diabetes in study groups. Timepoint: 8 weeks after intervention. Method of measurement: check list.;Incidence of urinary tract infection in the study groups. Timepoint: 8 weeks after intervention. Method of measurement: Laboratory and check list.;The mean of HbA1C in the study groups. Timepoint: 8 weeks after intervention. Method of measurement: Laboratory and check list.;The fetal biometric criterias (femur length, head circumference, biparietal diameter, abdominal circumference and fetal weight) in the study groups. Timepoint: 8 weeks after intervention. Method of measurement: Sonography and check list.;Incidence of preeclampsia in the study groups. Timepoint: 8 weeks after intervention. Method of measurement: The blood pressure according to millimeter of mercury by using a analog sphygmomanometer and random urine albumin by using diagnostic strips for urine protein assay.;Mothers satisfaction of the received drugs in the study groups. Timepoint: 8 weeks after intervention. Method of measurement: The check list of satisfaction of received drug. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShafaie sehhatie fahimeh
Faculty of nursing and midwifery
Outcome results
None listed